Cheng et al. reported that metformin, a commonly utilized medication for diabetes, worked synergistically to boost the antitumor effects of lenvatinib in HCC by promoting apoptosis and triggering cell cycle arrest through the modulation of the AKT-Forkhead box protein O3 (FOXO3) pathway 101. The gene discussed is AKT1; the disease is hepatocellular carcinoma.